JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Ten-year journey with myelofibrosis: real-world data and clinical outcomes from a tertiary care center
Abstract
Aims: The aim of this study was to document the last decade of experience with primary myelofibrosis (PMF) and provide mature risk-stratified survival data and disease complication estimates.
Methods: This retrospective study included all patients diagnosed with PMF according to World Health Organization criteria between 2009 and 2019 at İstanbul Medipol University. The follow-up period extended until March 2019.
Results: A total of 74 patients (median age 60.5 years, range 30-85) were included, with 35 males (47.3%) and 39 females (52.7%). During the study period, 34 deaths (45.9%), 3 leukemic transformations (4%), and 3 thrombotic events (4.2%) were recorded, including bilateral pulmonary artery thrombosis, cephalic vein thrombosis, and left lower extremity deep vein thrombosis. The median overall survival was 6 years. There was no statistically significant difference in life expectancy between patients treated with ruxolitinib and those receiving other medications (erythropoiesis-stimulating agents, androgens, immunomodulatory agents, cytoreductive drugs such as hydroxyurea, and splenectomy) (chi-square statistic: 3.5149, p = 0.0608). One of the 11 patients treated with ruxolitinib died (9%), while the remaining 10 patients survived (91%).
Conclusion: PMF remains a serious disease with high mortality and morbidity, requiring effective treatment interventions. Despite recent advances, treatment remains unsatisfactory for most patients. Although ruxolitinib, a JAK2 inhibitor, shows promise in managing symptoms, its impact on life expectancy remains unclear, highlighting the need for novel therapeutic strategies and well-designed clinical trials.

Keywords : Myelofibrosis, ruxolitinib, thrombosis, leukemic transformation, JAK2 inhibitor

Download Article


1. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood. 1978;51(2):189-194.
2. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol. 1999;17(9):2954-2970. doi:10.1200/JCO.1999. 17.9.2954
3. Vannucchi AM, Lasho T, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861-1869. doi:10.1038/leu.2013.119
4. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127. doi:10.1056/NEJMoa1002028
5. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-1097. doi:10.1182/blood-2007-04-083501
6. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-1708. doi:10.1182/blood-2009-09-245837
7. Szuber N, Mudireddy M, Nicolosi M, et al. 3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc. 2019;94(4):599-610. doi:10.1016/j.mayocp.2018.08.022
8. Pardanani A, Tefferi A. Definition and management of ruxolitinib treatment failure in myelofibrosis. Blood Cancer J. 2014;4(12):e268. doi: 10.1038/bcj.2014.84
9. Verstovsek S, Mesa RA, Gotlib J, et al. Long-term outcomes of ruxolitinib therapy in patients with myelofibrosis: 3-year update from COMFORT-I. Blood. 2013;122(21):396. doi:10.1182/blood.V122.21.396.396
10. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047-4053. doi:10.1182/blood-2013-02-485888
11. Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc. 2012;87(1): 25-33. doi:10.1016/j.mayocp.2011.11.001
12. Tefferi A, Lasho T, Finke C, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472-1477. doi:10.1038/leu.2014.3
13. García-Manero G, Schuster SJ, Patrick H, Martinez J. Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. Am J Hematol. 1999;60(2):130-135. doi:10. 1002/(sici)1096-8652(199902)60:2<130::aid-ajh8>3.0.co;2-z
14. Lopez-Mattei J, Verstovsek S, Fellman B, et al. Prevalence of pulmonary hypertension in myelofibrosis. Ann Hematol. 2020;99(4):781-789. doi: 10.1007/s00277-020-03962-2
15. Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507-2615. doi:10.1182/blood-2014-05-579136
16. Hussein K, Pardanani AD, Van Dyke DL, et al. International prognostic scoring system-independent cytogenetic risk categorization in primary myelofibrosis. Blood. 2010;115(3):496-499. doi:10.1182/blood-2009-08- 240135
Article available in :
Volume 3, Issue 3, 2025
Page : 57-61
https://doi.org/10.51271/JCHOR-0063
Article Information
Received : 12 Mar 2025
Accepted : 10 Haz 2025
Published : 08 Ağu 2025
Corresponding Author :

Berrin Balık: Department of Hematology, Faculty of Medicine, İstanbul Medipol University, İstanbul, Turkiye

[email protected]
Citation : Balık B, Akdeniz A, Koyuncu MB, et al. Ten-year journey with myelofibrosis: real-world data and clinical outcomes from a tertiary care center. J Curr Hematol Oncol Res. 2025;3(3):57-61.

Read: -103
Download : 537
Cited: 0
_Footer